Quarterly ResultApr 30, 2026, 04:56 PM
BAX Q1 Net Sales +2.9% to $2.7B; Net Loss $(15)M; EPS $(0.03)
AI Summary
Baxter International Inc. reported Q1 2026 net sales of $2.701 billion, a 2.9% increase year-over-year. However, the company posted a net loss attributable to stockholders of $(15) million, or $(0.03) diluted EPS, compared to a net income of $126 million and $0.25 diluted EPS in Q1 2025, primarily due to the prior year's gain from the Kidney Care divestment. Cash flows from continuing operations significantly improved to $213 million. The company also faces ongoing legal and regulatory matters, including Class I recalls for its Novum LVP and multiple lawsuits.
Key Highlights
- Net sales increased 2.9% to $2.701 billion for Q1 2026, up from $2.625 billion in Q1 2025.
- Net loss attributable to Baxter stockholders was $(15) million, or $(0.03) diluted EPS, in Q1 2026.
- This compares to net income of $126 million, or $0.25 diluted EPS, in Q1 2025, which included a $191 million gain from discontinued operations.
- Cash flows from continuing operations improved to $213 million in Q1 2026 from $(99) million in Q1 2025.
- Cash dividends declared per share significantly decreased to $0.01 in Q1 2026 from $0.17 in Q1 2025.
- Current maturities of long-term debt increased to $842 million as of March 31, 2026, from $2 million at Dec 31, 2025.
- Goodwill decreased to $4.899 billion and other intangible assets, net, to $4.218 billion as of March 31, 2026.
- Company is involved in multiple legal proceedings, including Class I recalls for Novum LVP and DOJ investigations.
Price Impact
More from BAX